Aptar Pharma will unveil Prohaler®, the smart DPI for optimal patient compliance - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

 

Aptar Pharma will unveil Prohaler®, the smart DPI for optimal patient compliance

During the next edition of CPHI/ICSE Europe tradeshow which be held on October 7th to October 9th, in Paris Villepinte, Aptar Pharma will introduce Prohaler®, the smart DPI for optimal patient.  

The Prohaler® DPI has been developed with a patient-based design approach which makes it intuitive and simple to use by all asthma and COPD patients.

Prohaler® features a novel powder dispersion technology enabling consistent lung deposition even while operating at relatively low patient inhalation flow rates. The results of a recent research showed that Prohaler® has excellent ergonomics, providing intuitive and constant handling characteristics. It is easy to use, with only 3 simple steps needed: open the device, inhale and close it; inhaling triggers the release of a full dose of medication. And a dose counter reminds the patient how many doses are left in the device.

Prohaler® incorporates visual and audible feed-back systems to facilitate ease-of-use and patient compliance.

Prohaler® also has a unique patient safety feature to avoid any risk of double-dosing and wasted doses. And the drug product is protected inside individual blisters which are only opened upon inhalation by the patient, providing optimal powder protection.

For more information on Prohaler®, please visit our booth #2F35, hall 2, or our website: www.aptar.com/pharma

Contact details:
Aptar Pharma
36-36 Rue de la Princesse
78431 Louveciennes Cedex - France
Telephone number: + 33 (0)1 39 17 20 20
Fax number: + 33 (0)1 39 58 12 98
Email: info.pharma@aptar.com
www.aptar.com/pharma

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
29%
Oversee medical treatment of patients in the US.
11%
Provide treatment for patients globally.
7%
All of the above.
46%
No government involvement in patient treatment or drug development.
7%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
FindPharma Custom Search

Click here